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1. Introduction 
Fibromyalgia patients are suffering distressing pain-centered symptoms, and therefore the 
clarification of fibromyalgia pathophysiology and the development of more effective 
therapeutic options are urgent issues. In the preclinical phase of analgesic drug 
development, experimental animal pain models have been widely used to investigate 
analgesic efficacies of candidate agents. In this approach, some kind of manipulations are 
conducted to induce clinically relevant pain states such as hyperalgesia and allodynia in the 
experimental animal, and then, pain-associated behaviors are measured as indicators of 
pain. Efficacy of test drugs on the said pain is finally evaluated. While animal pain models 
associated with neuropathy or inflammation have been well established and used in drug 
discovery research (Negus et al., 2006), only a few have been developed for examining 
fibromyalgia. This chapter focuses on the review of putative animal models of fibromyalgia, 
which mimic some features of patients with fibromyalgia. 
2. Challenges accompanying the development of fibromyalgia animal model 
Widespread chronic pain is a core symptom in fibromyalgia patients, and manifestation of 
this pain is a necessary and extremely important criterion in developing fibromyalgia 
animal models. Chronic pain can be categorized into three groups according to the 
mechanism underlying the pain: nociceptive pain, which is caused by tissue damage 
including inflammation; neuropathic pain, which is caused by a dysfunction in nerve fibers; 
and central (non-nociceptive) pain, where the central disturbance in pain processing is 
involved (Clauw, 2009). Animal models for nociceptive and neuropathic pain are well 
established and have significantly contributed to the development of therapeutic options 
since relatively early times (Negus et al., 2006), due in part to the relatively easy-to-mimic 
etiology of nociceptive and neuropathic pain. For example, controlled damage to the 
sensory nerve fibers by surgical, infectious, or chemical manipulation can effectively induce 
neuropathic pain, while damaging the tissues by surgical or inflammatory means can 
effectively induce nociceptive pain. On the other hand, the development of the animal 
model of central (non-nociceptive) pain is rather difficult due to the unknown etiology. 
Namely, it is challenging to specify the relevant trigger of experimental pain due to the poor 
understanding of the nociceptive source. Consequently, animal models for fibromyalgia, a 
disease that exhibits typical central (non-nociceptive) pain, are relatively naive. 
Also complicating such models is the fact that fibromyalgia is not a simple pain state but 
rather is accompanied by multiple comorbid symptoms including depression, fatigue, sleep 
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disturbance, irritable bowel syndrome, and irritable bladder syndrome (Clauw, 2009), and 
patients often experience one or more of these comorbidities in addition to widespread pain. 
One report plotted the prevalence of fatigue, sleep disturbance, and depression in 
fibromyalgia patients at approximately 80%, 90%, and 40%, respectively, although the 
prevalence varies across the population (Sluka, 2009). In 2010, new diagnostic criteria for 
fibromyalgia were proposed by the American College of Rheumatology (Wolfe et al., 2010). 
The criteria include widespread pain index, but no longer require tender point examination. 
Alternatively, they include severity scores of comorbid symptoms such as cognitive 
symptoms, unrefreshed sleep, and fatigue. Given this correlation between comorbidities and 
pain in fibromyalgia patients, corresponding animal models should ideally simulate the 
development of these symptoms in addition to chronic pain; concurrent consideration for 
depression, fatigue, and visceral organ function is important when investigating the chronic 
pain state in fibromyalgia animal models. 
Given that fibromyalgia predominantly occurs in women, it would be worth to consider the 
involvement of female animals in the construction of fibromyalgia animal model. However, 
because estrous cycle influences nociceptive processing in both peripheral and central 
pathways (Fillingim and Ness, 2000), this cycle could be a confounding bias in the 
preclinical pain research. Thus, it would be necessary to assess carefully the estrous cycle 
phase when using female animals in preclinical experiment. 
3. Hypotheses for fibromyalgia pathogenesis 
Several hypotheses have been proposed regarding fibromyalgia pathogenesis and should be 
considered when designing a suitable animal model. 
Fibromyalgia is generally considered to be a stress-related disorder. Stress plays an 
exacerbating role in the development of somatic symptoms including chronic pain. There is 
evidence that disparate stressful events including childhood abuse and physical traumas 
would trigger the development of fibromyalgia (Clauw, 2009).  
Alternatively, an abnormal neuroendocrine system may be involved in the pathogenesis, as 
stress affects the hypothalamic-pituitary-adrenal axis and the autonomic nervous system. 
Indeed, altered function of the hypothalamic-pituitary-adrenal axis has been detected in at 
least some subpopulation of fibromyalgia patients, and aberrations in the autonomic 
nervous system are also often observed (Bradley, 2009). 
Many fibromyalgia patients experience pain in deep tissues such as muscle. Abnormalities 
in the local muscle tissue may therefore underlie the pathogenesis, as changes of 
intramuscular microcirculation or muscle energy metabolism have been detected in the 
musculoskeletal tissue of some fibromyalgia patients. This localized muscle pain may 
eventually spread throughout the body via a central nervous system-mediated mechanism, 
thereby leading to nociceptive input from the deep tissue and generating central 
sensitization in the spinal cord and brain. After this central sensitization is established, a 
chronic pain state can be maintained by even minimal nociceptive input from the peripheral 
tissues (Nielsen & Henriksson, 2007). The pain assessment by using spinal nociceptive 
flexion reflex (NFR), a correlate for the evaluation of central nociceptive pathways, suggests 
that abnormally processed nociceptive signal input to central nociceptive pathways (i.e., 
central sensitization) underlies the pathophysiology in fibromyalgia patients (Desmeules et 
al., 2003). Also, attenuation of inhibitory pain control in the central nervous system seems to 
be involved in development of fibromyalgia. Ascending nociceptive input to the supraspinal 
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brain is down-regulated by the brainstem descending pain inhibitory pathway, where 
neurotransmitters associated with the regulation of both pain and mood operate. 
Dysfunction in this inhibitory pain control has been suggested to play an important role in 
the pathogenesis of fibromyalgia. Indeed, diffuse noxious inhibitory control (DNIC), an 
indicator for activity in the central descending pain inhibitory pathway, has been found to 
be attenuated in many fibromyalgia patients (Clauw, 2009). 
4. Approach for developing fibromyalgia animal models 
Given the different etiology between fibromyalgia (central pain) and 
nociceptive/neuropathic pain, animal models more specific to fibromyalgia need to be 
developed. In this chapter, we discuss several noteworthy animal models that mimic certain 
major fibromyalgia features based on three types of validation: construct validity (“Is 
induction of the disease state in accordance with the fibromyalgia etiology?” Animal models 
should be constructed based on the aforementioned hypotheses), face validity (“Do 
fibromyalgia-like symptoms successfully manifest?” Animal models should exhibit chronic 
pain symptoms and accompanying comorbidities), and predictive validity (“How do the 
symptoms respond to treatments used in the clinical setting?” Although some drugs have 
been approved for the treatment of fibromyalgia-associated pain, the effect size of these 
drugs seems not sufficient). 
5. Key animal models 
The animal models to be reviewed in this chapter are the repeated cold stress model, the 
unpredictable sound stress model, the intramuscular acidic saline injection model, and the 
reserpine-induced myalgia model, in which assumed causes of chronic pain are unavoidable 
stress, stress-induced disruption of the neuroendocrine system, an initial local muscle 
abnormality that spreads throughout the body, and dysfunctional pain control in the central 
nervous system, respectively. All four models operate on the common premise that once 
chronic pain is established, no apparent organic disorder can explain its persistence. Further, 
the pain symptoms are not localized to the ipsilateral side, instead spreading to the 
contralateral side of the body as well. 
5.1 Repeated cold stress model 
5.1.1 Methods 
The repeated cold stress model was first introduced as an animal model to study autonomic 
imbalance in response to sudden changes in environmental temperature (Kita et al., 1975; 
Ohara et al., 1991). Mice exposed to repeated cold stress develop several abnormal 
physiologies such as a continuous lowering of blood pressure, sympathicotonic-type 
electrocardiogram (ECG), depression-like behaviors, and hyperalgesia (Ohara et al., 1991). 
In this model, animals (usually mice) are kept in a room at a temperature alternating 
between 24 and 4C every hour in the day time, and then kept at 4C overnight. This 
procedure was repeated for 5 days or more (Kita et al., 1975; Hata et al., 1995). 
Nishiyori and Ueda (2008) revisited this stress model to demonstrate its utility as a putative 
animal model for fibromyalgia. They optimized the repeated cold stress protocol to induce 
long lasting mechanical and thermal hyperalgesia in mice as follows. On Day 1, the 
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experiment starts with exposing mice to a cold temperature (4C) overnight until morning 
the next day. From there, the temperature is then alternated between 24 and 4C every 30 
min in the day time. This is repeated until morning on Day 4. A nociception test is then 
conducted at room temperature at least 1 h after the end of stress exposure. 
5.1.2 Primary features 
Nishiyori and Ueda (2008) found that mice exhibited thermal hyperalgesia (reduction in 
paw withdrawal latency in response to thermal stimulation) and mechanical hyperalgesia 
(reduction in threshold for paw withdrawal in response to mechanical stimulation by the 
von Frey apparatus) for more than 12 days following the repeated cold stress. In contrast, 
mice exposed to constant cold temperature (4C) stress manifest only short-lasting 
hyperalgesia. Similarly, the repeated cold stress with the protocol by Ohara et al. (1991) 
caused mechanical hyperalgesia, which was maintained for 1 week after the start of stress 
loading, in the tail pressure test in mice. 
5.1.3 Constructive validity 
Stressors such as physical trauma, catastrophic events, hormonal alterations, and emotional 
stress play an important role in triggering development of fibromyalgia. Individuals 
exposed to these stressors have been found to develop chronic widespread pain with a 
relatively high probability, as indicated by studies investigating the effects of childhood 
abuse and posttraumatic stress disorder. Similarly, studies using animals have suggested 
that stressors that can neither be avoided nor controlled are more likely to cause unstable 
physiological responses and may lead to irreversible health problems (Clauw, 2009). This 
means that disparate stressors are potential factors in triggering development of 
fibromyalgia. 
Stressors may affect physiological function by altering the hypothalamic-pituitary-adrenal 
axis and causing a malfunction in autonomic control. Dysfunctional autonomic control may 
then, in turn, associate with fibromyalgia pathogenesis. For example, the abnormality in 
heart rate variability, which suggests an autonomic dysfunction, is raised as a risk factor of 
fibromyalgia (Clauw, 2009). 
Based on the suggested involvement of stressors and the dysfunction of neuroendocrine 
system in the pathogenesis of fibromyalgia, the sudden and frequent change in 
environmental temperature, which has been known to cause autonomic imbalance and 
hyperalgesia (Hata et al., 1988), is utilized to cause a long-lasting mechanical and thermal 
hyperalgesia in animals in the repeated cold stress model. Interestingly, it is not simply 
constant cold stress but rather repeated cycling of cold stress that causes long-lasting 
hyperalgesia. This may mean that animals are capable of adapting to cold environmental 
temperature exposure over a long period, but a sudden and frequent environmental 
temperature change such as that experienced in the repeated cold stress greatly affects 
physiological function, including autonomic control. This dysfunction in autonomic 
control and subsequent development of chronic pain state may be due to changes in 
certain neurotransmitters, as the repeated cold test has been found to also decrease 
serotonin and increase noradrenaline and dopamine in the central nervous system (Hata 
et al., 1987; Hata et al., 1991). The turnover of serotonin in the spinal cord is accordingly 
reluctant to be activated in mice following exposure to repeated cold stress (Nishiyori et 
al., 2010). 
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5.1.4 Face validity 
The repeated cold stress test performed by Nishiyori and Ueda (2008) caused long-lasting 
(12 days or more) mechanical and thermal hyperalgesia in the paws of both male and female 
mice, suggesting no apparent difference in susceptibility to repeated cold stress between 
genders. Intriguingly, gonadectomized male mice showed partial reversal of the repeated 
cold stress-induced mechanical hyperalgesia, whereas gonadectomized females did not. 
This difference may be related to the predominance of chronic pain occurrence in female, 
which is a feature of fibromyalgia epidemiology (Clauw, 2009). 
In addition to hyperalgesia, the repeated cold stress causes abnormal behaviors in mice, a 
feature that may be associated with the comorbid symptoms seen in fibromyalgia patients. 
Mice loaded with repeated cold stress show a shortened immobility time in the forced swim 
test, a test used to assess the anti-depressive effect of drugs. Although prolonged immobility 
time is typically associated with depressed condition, the authors suggest that the reduced 
immobility time may also indicate complex symptoms such as excessive emotion- or 
anxiety-related depression, as immobility time recovered when the mice were given 
repeated injections of antidepressants or a single injection of anxiolytics (Hata et al., 1995). 
5.1.5 Predictive validity 
Gabapentin is structurally related to pregabalin, which has been approved for treatment of 
fibromyalgia in the USA. It is  a ligand for the α2δ1 subunit in voltage-dependent calcium 
channels as is pregabalin. Gabapentin was approved for the treatment of neuropathic pain 
such as post herpetic neuralgia, and was statistically more effective than placebo in reducing 
pain scores in a 12-week randomized controlled trial in fibromyalgia patients (Arnold et al., 
2007). Regarding the effect size in this trial, reduction of >or=30% in average pain severity 
score (range 0-10, where 0=no pain and 10=pain as bad as you can imagine) was 51% for 
gabapentin and 31% for placebo. 
In the repeated cold stress model, gabapentin completely recovered both mechanical and 
thermal hyperalgesia. This efficacy of gabapentin is basically consistent with the study 
showing that pregabalin significantly attenuates the pain score in phase III clinical trials  
for fibromyalgia patients (Mease et al., 2008). In mice, the effective dose for relieving 
hyperalgesia in the repeated cold stress model was over three times smaller than that for 
reducing nerve injury-induced neuropathic pain, despite the effective dose of pregabalin 
being similar between fibromyalgia and neuropathic pain patients in a clinical setting 
(Dworkin et al., 2007; Mease et al., 2008). Further, intracerebroventricular administration of 
gabapentin significantly attenuated hyperalgesia in the repeated cold stress model but not in 
the neuropathic pain model, possibly because up-regulation of the α2δ1 subunit may underlie 
the mechanism for repeated cold stress-induced hyperalgesia (Nishiyori and Ueda, 2008). 
No clear evidence has yet been presented that opiate drugs are effective in reducing pain in 
fibromyalgia patients, as no randomized controlled double blind clinical trial on opiates has 
been conducted with a sufficient number of fibromyalgia patients (Clauw, 2009). One study 
using a small number of fibromyalgia patients did not detect any significant benefit when 
intravenously injecting morphine (Sörensen et al., 1995). In accordance with these findings, 
neither subcutaneous nor intracerebroventricular injection of morphine has been found  
to attenuate thermal hyperalgesia in repeated cold stressed mice. Given that serotonin 
turnover is unlikely to be accelerated by morphine in these animals, a dysfunction in the 
serotonin-mediated descending inhibitory pathway might explain the absence of morphine 
analgesia (Nishiyori et al., 2010). 
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Neurotropin is an extracted substance from the inflamed skin of rabbits inoculated with 
vaccinia virus. It has been used in the treatment of chronic pain including post-herpetic 
neuralgia in Japan. The analgesic mechanism of neurotropin has not been fully clarified. 
However, the enhancement of descending pain inhibitory pathway could be involved in the 
mechanism and the intraperitoneal injection of neurotropin significantly attenuates the 
mechanical hyperalgesia in the repeated cold stressed mice (Ohara et al., 1991). There has 
been no study with a sufficient number of fibromyalgia patients so far, which suggests that 
neurotropin has beneficial effect in the treatment of fibromyalgia. 
5.2 Unpredictable sound stress model 
5.2.1 Methods 
In this model, animals (usually male rats) are placed in a sound box for 30 min, during 
which they are randomly exposed every minute to unpredictable sounds ranging in 
amplitude from 20 to 105 dB and several frequencies for 5 or 10 sec each. Following the test, 
the animals are returned to their home cage. The sound stress protocol is conducted on Days 
1, 3, and 4. Nociceptive and other behavioral experiments are conducted typically 1 or 14 
days after the last sound stress delivery (Green et al., 2011; Khasar et al., 2005). 
5.2.2 Primary features 
Sound-stressed rats exhibit an aggravation of algesic substances (bradykinin or 
prostaglandin E2)-induced mechanical hyperalgesia in the paw and muscle pressure tests, 
although they do not manifest hyperalgesia without the application of an algesic substance. 
These animals also manifest visceral hypersensitivity based on colorectal distension 14 days 
after the end of stress, even without application of exogenous algesic substances. Anxiety 
score as measured by the elevated plus maze test is also increased 14 days after the last 
stress exposure (Green et al., 2011; Khasar et al., 2005). 
5.2.3 Constructive validity 
Stress has been shown to be a risk factor for fibromyalgia development, as traumatic events 
are likely to trigger chronic pain symptoms (Clauw, 2009). Dysfunction in sound stressor 
processing has been shown to occur in some fibromyalgia patients (Dohrenbusch et al., 
1997), and stressors in general have been known to affect physiological functions such as 
nociception by changing the sympathoadrenal (adrenaline) and hypothalamic-pituitary-
adrenal (corticosterone) axes in the neuroendocrine system. Because unpredictable sound 
stress affects both axes and causes a prolonged elevation of plasma adrenaline levels, the 
stress-induced release of adrenaline (the product of neuroendocrine system activation) 
likely plays an important role in developing mechanical hyperalgesia in the unpredictable 
sound stress model. This working hypothesis is consistent with evidence of elevated plasma 
adrenaline levels and enhanced bradykinin-induced mechanical hyperalgesia in 
vagotomized rats (Khasar et al., 1998; Khasar et al., 2003; Levine and Reichling, 2005). 
Hypersensitivity in the presence of pronociceptive substances is commonly observed in 
fibromyalgia patients (Wang et al., 2008), and the requirement of pronociceptive substances 
for sound-stressed animals to exhibit enhanced somatosensory function may reflect a similar 
feature. However, the lack of change in the baseline nociceptive threshold in the 
unpredictable sound stress model is inconsistent with changes noted with other types of 
stressors such as repeated cold stress (Nishiyori and Ueda, 2008) and repeated swim stress 
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(Quintero et al., 2000). This difference may be because of the type of stressor or because of 
the method for measuring nociceptive function. Additionally, visceral hypersensitivity 
manifests even without the addition of pronociceptive substances, possibly due to the 
presence of endogenous pronociceptive substances in the gastrointestinal tissues, as these 
make sound stress-induced hyperalgesia be elicited (Green et al., 2011). 
5.2.4 Face validity 
In humans, chronic pain symptoms tend to develop on a delay after a traumatic event (Roy-
Byrne et al., 2004). In line with this observation, sound-stressed rats develop an enhanced 
nociceptive response to pronociceptive substances such as bradykinin and prostaglandin E2 
in the skin and muscle region not on Day 1 but on Day 14 after the end of stress exposure. 
Although fibromyalgia patients show somatic hypersensitivities to mechanical stimuli 
without exogenous application of pronociceptive substances, unpredictable sound stress 
does not cause significant changes in somatic sensitivity to mechanical stimuli unless 
pronociceptive substances are applied. Instead, plasma cytokine levels associating with the 
hypersensitivity seen in fibromyalgia patients (Wang et al., 2008) correlate with repeated 
sound stress exacerbating the pronociceptive substance-induced nociceptive response. 
Further, visceral hypersensitivity manifests even without the addition of exogenous 
pronociceptive substances (Green et al., 2011). 
Similar to fibromyalgia patients who show comorbid symptoms such as irritable bowel 
syndrome, temporomandibular disorder, and anxiety (Clauw, 2009), sound-stressed rats 
manifest typical comorbid symptoms such as visceral hyperalgesia, temporomandibular 
hyperalgesia and an elevation of anxiety score on Day 14 after the end of stress exposure 
(Green et al., 2011). Abnormalities in the hypothalamic-pituitary-adrenal axis and 
sympathetic nervous system have also been suggested to occur in at least a subpopulation of 
fibromyalgia patients (Clauw, 2009), and indeed, sound-stressed rats manifest a long-lasting 
elevation of plasma adrenaline concentration (Khasar et al., 2005). 
5.2.5 Predictive validity 
Little information is available regarding the pharmacotherapeutic efficacy on nociceptive 
responses induced by sound stress-induced exacerbation so far. However, because adrenal 
medullectomy but not sympathectomy inhibits this exacerbation, adrenaline derived from 
the adrenal medulla appears to play a primary role in the exacerbation mechanism in this 
model (Khasar et al., 2005). Pharmacotherapy for correcting the neuroendocrine abnormality 
may improve the enhanced sensitivity. 
5.3 Intramuscular acidic saline injection model 
5.3.1 Methods 
Rats are typically used in this model. Each animal receives two repeated 100-µl injections of 
acidic saline (adjusted to pH 4.0) in the same unilateral gastrocnemius muscle under inhaled 
anesthesia, a procedure which is repeated five days later (Sluka et al., 2001). 
5.3.2 Primary features 
After the second injection of acidic saline, the animal manifests bilateral cutaneous and 
muscle mechanical hyperalgesia, which is detected as a reduction in the paw withdrawal 
threshold based on the von Frey filament test and the muscle pressure test in the 
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gastrocnemius muscle. These hyperalgesia symptoms are long-lasting (two weeks or more). 
However, the animal does not exhibit thermal hyperalgesia, which is measured based on 
paw withdrawal latency in the radiant heat exposure test. The rat displays no motor 
impairment, as assessed by the treadmill test, nor any histopathological change specific to 
the acidic acid saline injection in the affected gastrocnemius muscle (Sluka et al., 2001; 
Yokoyama et al., 2007). 
5.3.3 Constructive validity 
In humans, local acidity in the muscle or skin has several causes, including inflammation 
and ischemia, and can induce pain initially at a local region. A previous study found that 
muscle pain is caused by an infusion of acid phosphate buffer into the forearm muscle 
(Issberner et al., 1996). Another study (Graven-Nielsen et al., 1997) showed that repeated 
infusion of hypertonic saline caused the pain to diffuse from the primary infusion site 
(tibialis anterior muscle) to other regions like the ankle. The intensity of the diffused pain 
becomes larger in the short interval of infusion than in the long interval. Taken together, 
these previous findings suggest that repeated infusions of saline into the muscle can cause 
pain to spread beyond the original local region. This spreading may be analogous to the 
widespread musculoskeletal pain that is a main feature in fibromyalgia. Based on the 
working hypothesis that the spread of initially localized pain underlies the process of 
fibromyalgia development, the acidic acid injection was used as the trigger of wide 
spreading pain in the intramuscular acidic saline injection model. In consistent with the 
clinical features, not single but repeated injections successfully induced the chronic 
mechanical hyperalgesia in cutaneous and muscle tissues outside the area of injection, both 
ipsilaterally and contralaterally. 
Regarding the mechanism of this spreading in fibromyalgia patients, several studies have 
suggested involvement of enhanced synaptic activity in the central nervous system, 
including the spinal cord, and an attenuation of descending inhibitory control from 
supraspinal centers (Graven-Nielsen and Arendt-Nielsen, 2010). Actually, the nociceptive 
flexion reflex (NFR), a psychophysiological tool to study spinal nociceptive process (France 
et al., 2009), suggests that central sensitization is involved in fibromyalgia pain as a key 
mechanism (Desmeules et al., 2003). Since an injection of lidocaine into the ipsilateral 
gastrocnemius muscle did not affect the spreading of pain, it is unlikely that the continuous 
nociceptive signal input from the primary afferent neurons is mainly implicated in the 
spreading of pain in the intramuscular acidic saline injection model. Alternatively, the 
development of contralateral hyperalgesia implies the involvement of central mechanism. 
Actually, intrathecal administration of glutamate receptor antagonists after the second 
acidic acid saline injection inhibits the spreading of pain (Skyba et al., 2002), and the 
injection of a local anesthetic or a N-methyl-D-aspartate (NMDA) receptor antagonist into 
the rostral ventromedial medulla, which plays a critical role in the descending pain control, 
also prevents the development of the bilateral hyperalgesia (Tillu et al., 2008; Da Silva et al., 
2010). Further, activation of mu- and delta-opioid receptors in the spinal cord attenuates the 
hyperalgesia (Sluka et al., 2002). These evidences suggest that the sensitization mainly in the 
spinal cord level rather than the peripheral level and the modulation of descending pain 
control pathway underlie the pathophysiology in this model in accordance with existing 
theories for the pathophysiology in fibromyalgia patients (Clauw, 2009). 
www.intechopen.com
 
Animal Models of Fibromyalgia 
 
49 
5.3.4 Face validity 
The nociceptive source of fibromyalgia pain has yet to be identified. In general, no apparent 
inflammation or tissue injury can explain the pain endured by fibromyalgia patients. In line 
with this, no specific pathological changes specific to acidic saline injection have been 
detected (Sluka et al., 2001), meaning no organic disorder has been identified that can 
explain the widespread pain. 
Intramuscular acidic saline injection model rats develop long-lasting bilateral muscle 
hyperalgesia (Yokoyama et al., 2007) in accordance with the deep tissue hyperalgesia and 
existence of tender points around the body seen in fibromyalgia patients. These animals also 
exhibit chronic cutaneous tactile allodynia, also consistent with findings in fibromyalgia 
patients. However, these animals do not develop thermal hyperalgesia (Sluka et al., 2001). 
Instead, visceral hyperalgesia detected by electromyography occurs concurrently with 
somatic hyperalgesia, suggesting that somatic afferent input from the gastrocnemius muscle 
induces visceral hyperalgesia, possibly via viscerosomatic convergence at the level of the 
lower spinal cord (Miranda et al., 2004). This finding is consistent with those in fibromyalgia 
patients who frequently show abdominal hypersensitivity, such as irritable bowel 
syndrome. 
5.3.5 Predictive validity 
A phase III clinical trial with fibromyalgia patients showed that pregabalin is efficacious and 
safe for use in treating pain associated with fibromyalgia, although it frequently causes 
dizziness and somnolence (Mease et al., 2008). A recent systematic review of the 
effectiveness of antiepileptic drugs for fibromyalgia suggests that pregabalin is modestly 
effective, although long-term safety and efficacy results are unavailable (Siler et al., 2011). In 
intramuscular acidic saline injection model, pregabalin significantly recovers the lowered 
mechanical thresholds at a dose range of 10-100 mg/kg i.p. but significantly reduces motor 
function outcome, as determined by the rota-rod performance test, at 30 mg/kg i.p. or more 
(Yokoyama et al., 2007). This result may reflect the clinically narrow margin between 
analgesic and dizzying doses. 
5.4 Reserpine-induced myalgia (RIM) model 
5.4.1 Methods 
Rats are usually used. They are housed individually in the cage and are subcutaneously 
administered reserpine at 1 mg/kg once daily for three consecutive days. Hyperalgesia is 
typically evaluated on Day 5 after the last reserpine injection (Nagakura et al., 2009). 
Because tenderness to palpation is a diagnostic criterion for fibromyalgia and blunt pressure 
loading is frequently used to estimate muscular pain thresholds in humans, the muscle 
pressure test is used (Petzke et al., 2003). 
5.4.2 Primary features 
In male and female rats, repeated administration of reserpine significantly reduced the 
muscle pressure threshold based on muscle pressure test results and tactile allodynia based 
on the von Frey hair test results, lasting for more than one week. This administration 
decreased the amount of biogenic amines (dopamine, norepinephrine, and serotonin) in the 
spinal cord, thalamus, and prefrontal cortex, all of which are responsible for pain signal 
processing in the central nervous system. Further, reserpine significantly increased the 
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immobility time in the forced swim test, which is indicative of depression, a common 
comorbid symptom in fibromyalgia patients. However, the general condition of the animals 
did not deteriorate, as both tremor and hypokinesia symptoms disappeared by Day 3 or 
later after the last reserpine injection. Additionally, no significant difference was noted in 
either blood pressure or rectal temperature between reserpine- and vehicle-treated groups. 
Taken together, these findings suggest that reserpine produces chronic pain symptoms and 
depressive conditions by influencing pathways that regulate nociception and depression 
(Nagakura et al., 2009). 
5.4.3 Constructive validity 
Functional magnetic resonance imaging studies have shown augmented central pain 
processing in fibromyalgia patients. This augmented processing can be thought of as a 
central nervous system that is hyper-reactive to a wide range of stimuli (Clauw, 2009). While 
several transmitters have been known to play a role in excitatory and inhibitory pain control 
in the central nervous system, biogenic amines like dopamine, norepinephrine, and 
serotonin are particularly important for analgesic control in the descending inhibitory 
pathway in the brainstem (Mense, 2000; Wood, 2008). Therefore, it is plausible that a 
dysfunction in biogenic amine-mediated inhibitory pain control underlies the central 
augmentation and pain-centered complex symptoms seen in fibromyalgia patients. 
Concentrations of biogenic amines in cerebrospinal fluid have been reported to be 
significantly lower in fibromyalgia patients (17 female participants) than non-fibromyalgia 
subjects (Russell et al., 1992), and a profound disruption of dopamine release in the basal 
ganglia in response to painful stimulation in the muscle has been observed in fibromyalgia 
patients (Wood, 2008). Further, interruption of the descending pain inhibitory pathway in 
the brainstem causes augmented background activity and increased responsiveness to 
noxious stimulations in spinal nociceptive neurons (Mense, 2000). In addition to their 
involvement in pain control, biogenic amines in the central nervous system are closely 
related to the pathophysiology of major depressive disorders (El Mansari et al., 2010). 
Accordingly, depression is a potentially serious adverse effect when clinically administering 
reserpine (Leith and Barrett, 1980). 
The RIM model uses reserpine to deplete biogenic amines from the nervous system by 
irreversibly binding to monoamine transporters for storage vesicles. Repeated 
administration of reserpine in RIM rats causes a chronic decrease in dopamine, 
norepinephrine, and serotonin in several brain regions and concomitantly induces a 
decrease in muscle pressure threshold and tactile allodynia for at least one week. The time 
courses of the changes in biogenic amines concentrations and muscular/tactile response 
thresholds generally correlate, supporting the assumption that the observed chronic pain 
symptoms are caused by the attenuation of biogenic amine-mediated central nervous 
system pain control. These observations are all in accordance with the critical role of 
biogenic amines in analgesic control. Further, reserpine treatment also induces a depressive 
condition, consistent with the role biogenic amines have in the pathophysiology of 
depression. Because a short-term depletion of biogenic amines by tetrabenazine did not 
significantly affect nociceptive sensitivities, long-term depletion is likely necessary for 
chronic pain symptoms to develop (Nagakura et al., 2009; Oe et al., 2010). 
Intriguingly, in the experiment using single injection of reserpine, hyposensitivity to muscle 
pressure stimulus occurred in the acute phase (within 24 h) after the reserpine injection, 
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although hypersensitivity developed in the chronic phase, i.e., on Day 2 or later after the 
injection. The dynamic change of brain biogenic amine tones observed after the single 
injection of reserpine, which was indicated by the ratio of biogenic amine 
metabolite/biogenic amine, in the central nervous system seemed to correlate with the 
determination of nociceptive sensitivity (Oe et al., 2010). 
5.4.4 Face validity 
Fibromyalgia patients suffer chronic widespread musculoskeletal pain symptoms including 
tenderness to palpation. In line with this, both male and female RIM rats show a reduced 
muscle pressure threshold and tactile allodynia for at least one week after injection. Cold 
and heat hypersensitivities have also been reported to follow reserpine treatment (Oe et al., 
2010), paralleling the hypersensitivities to mechanical and thermal stimuli seen in 
fibromyalgia patients. In addition to chronic widespread pain symptoms, fibromyalgia is 
also characterized by comorbid affective disorders such as depression. Similarly, reserpine 
treatment prolongs the immobility time in the forced swim test for up to two weeks in RIM 
rats (Nagakura et al., 2009). 
Disturbances in the central nervous system is assumed to be involved in both the wide 
spread pain symptoms and the disturbance in the physiology of sleeping-waking 
(Moldofsky, 2010). Actually, fibromyalgia patients prevalently experience unrefreshed sleep, 
which is involved as one of factors in the new fibromyalgia criteria (Wolfe et al., 2010). 
Because dopamine, norepinephrine, and serotonin in brain neurological circuits are 
considered to play an important role in the regulation of complex sleep-waking cycle 
(Murillo-Rodríguez et al., 2009), depletion of brain biogenic amines by reserpine may cause 
a disturbance of sleep-waking cycle in addition to the hyperalgesia. Actually, it has been 
reported that reserpine treatment significantly affects the sleep cycle including rapid eye 
movement (REM) sleep and slow-wave sleep (Hoffman & Domino, 1969). It is of interest to 
investigate the sleep-waking cycle in RIM rats.  
5.4.5 Predictive validity 
A recent clinical study has suggested that pregabalin significantly relieves fibromyalgia pain 
symptoms compared to the placebo (Mease et al., 2008). This clinical beneficial effect is 
consistent with the result in the RIM rat that the muscle mechanical hyperalgesia is 
attenuated by pharmacotherapy with pregabalin. Other drugs approved for the treatment of 
fibromyalgia are duloxetine and milnacipran, which enhance norepinephrine and serotonin 
neurotransmission in the descending analgesic pathway. They significantly reduce the 
fibromyalgia pain symptoms in the phase III clinical trials (Clauw et al., 2008; Russell et al., 
2008). Duloxetine has been shown to significantly recover muscle hyperalgesia but not 
tactile allodynia in RIM rats. Further, the dopamine receptor agonist pramipexole has been 
shown to be efficacious in treating fibromyalgia pain symptoms in a phase II clinical study 
(Holman and Myers, 2005). In line with this, pramipexole attenuates muscle hyperalgesia 
and tactile allodynia at doses that cause hyper-locomotion in RIM rats. In contrast, 
diclofenac shows no significant efficacy in RIM rats, a finding consistent with evidence that 
non-steroidal anti-inflammatory drugs do not improve pain in fibromyalgia patients 
(Goldenberg et al., 1986; Yunus et al., 1989). The good correlation of analgesic efficacy 
mentioned above demonstrates the predictive validity of the RIM model (Nagakura et al., 
2009). 
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Model Constructive validity Face validity Predictive validity 
Repeated cold 
stress 
 Exposure to difficult-
to-adapt stressors 
 Dysfunction of 
autonomic control 
 Decrease in serotonin-
mediated central 
nervous system control
 Long-lasting 
mechanical and thermal 
hyperalgesia  
 Relief from 
hyperalgesia by 
gonadectomy in male 
mice only  
 Shortened immobility 
time in forced 
swimming test and 
reversal by 
antidepressants 
 Gabapentin  
(an analogue of 
pregabalin) is 
highly effective  
 Neurotropin  
(an extracted 
substance from 
inflamed skin) is 
effective  
 Small efficacy of 
morphine 
Unpredictable 
sound stress 
 Exposure to 
unpredictable stress  
 Appearance of 
hypersensitivity in the 
presence of 
pronociceptive 
substances 
 Stress-induced release 
of adrenaline (product 
of neuroendocrine 
system activation) 
 Enhancement of 
nociceptive response to 
pronociceptive 
substances  
 Delayed onset of 
hypersensitivity after 
stress exposure  
 Comorbidities including 
visceral hyperalgesia, 
temporomandibular 
hyperalgesia, and 
anxiety 
 Adrenal 
medullectomy 
inhibits the 
occurrence of 
hypersensitivity 
Intramuscular 
acidic saline 
injection 
 Local acidic condition 
in the muscle  
 Ipsilateral and 
contralateral spreading 
of hyperalgesia beyond 
the original local region 
 Involvement of central 
nervous system in 
spreading 
 Long-lasting bilateral 
muscle hyperalgesia 
 Chronic cutaneous 
tactile allodynia  
 Visceral hyperalgesia 
occurs concurrently 
with somatic 
hyperalgesia 
 Pregabalin recovers 
mechanical 
hyperalgesia but 
concurrently affects 
motor function at 
similar doses  
Reserpine-
induced 
myalgia 
 Dysfunction of 
biogenic amine-
mediated analgesic 
control in the central 
nervous system  
 Time courses of 
changes in biogenic 
amine concentrations 
and muscular/tactile 
response thresholds 
generally correlate 
 Long-lasting muscle 
hyperalgesia 
 Chronic cutaneous 
tactile allodynia  
 Comorbid depression 
 Pregabalin 
attenuates 
hyperalgesia  
 Duloxetine  
(a biogenic amines 
reuptake inhibitor) 
and pramipexole  
(a dopamine 
receptor agonist) 
are effective 
 Diclofenac is not 
effective 
Table 1. Constructive, face, and predictive validities of putative animal models for 
fibromyalgia. 
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6. Other relevant animal models 
In addition to the above-mentioned four models, several other models mimicking 
fibromyalgia symptoms have been developed. These models also reveal no apparent organic 
disorders that can explain the source of chronic pain symptoms, unlike neuropathic and 
inflammatory pain animal models. 
Biochemical and pharmacological studies have found that vagotomy in the stomach 
(subdiaphragmatic vagotomy) induces cutaneous (Khasar et al., 1998), visceral 
(Gschossmann et al., 2002) and muscle (Furuta et al., 2009) hyperalgesia in rats in a manner 
that resembles hyperalgesia in fibromyalgia patients. 
Chronic exposure to stressors other than those described above also produces enhanced 
nociception in animals. The forced swim stress (10-20 min of forced swimming for 3 
consecutive days) induces sustained thermal hyperalgesia and increased nociceptive 
behavior according to the formalin test (Quintero et al., 2000). Chronic restraint stress 
caused by wrapping with soft wire mesh (Imbe et al., 2004) or restraint in a cylinder (Bardin 
et al., 2009) also causes thermal hyperalgesia, mechanical allodynia, or cold allodynia in rats. 
The thermal hyperalgesia induced by wrapping seems to be associated with a significant 
change in the regulation of extracellular signal-regulated kinase (ERK) in the descending 
pain control pathway of the central nervous system (Imbe et al., 2004). 
Delayed onset of muscle soreness often occurs in humans after exercise. In accordance with 
this, inducing eccentric contractions in the extensor digitorum longus muscle causes 
delayed, long-lasting muscle hyperalgesia in rats (Taguchi et al., 2005). 
7. Future research 
Comparative mechanistic analysis of the animal models introduced in this chapter may 
clarify common and different pathways underlying those models. For example, it may be of 
interest to investigate whether there are causal changes in biogenic substances (e.g., 
hormones and neurotransmitters) common in those models. Investigation of the mechanism 
responsible for the different phenotypes among those models may be another interest. Such 
analysis may shed light on the true nature of fibromyalgia pathophysiology. 
Different time course of disease development between fibromyalgia patients and animal 
models need to be taken into consideration. Animals introduced in this chapter develop 
disease condition with shorter time course than fibromyalgia patients. It may be a future 
issue to establish and use naturally occurring chronic pain models which develop 
fibromyalgia-like conditions over slower time course. 
To date, studies using the above-mentioned models have mainly focused on the induction of 
pain symptoms such as mechanical and thermal hyperalgesia. While this is certainly a 
reasonable approach when developing animal models for fibromyalgia, as a major symptom 
in fibromyalgia patients is chronic, widespread pain, these patients also frequently show 
comorbid symptoms such as fatigue, sleep disturbance, cognitive impairment, irritable 
bowel, depression, and anxiety. Future research should therefore consider how to 
incorporate such comorbid symptoms into animal models. 
Other investigations may consider fibromyalgia biomarkers, as alterations in certain 
biochemical substances, physiological vital signs, and brain imaging have been reported to 
occur in fibromyalgia patients (Dadabhoy et al., 2008). These would also be potential 
biomarkers in animal models. Such investigations would add great value to our limited 
understanding of fibromyalgia, and support new diagnostics and drug development. 
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8. Conclusion 
As with nociceptive and neuropathic pain, animal models for fibromyalgia are strongly 
expected to contribute to our understanding of fibromyalgia pathophysiology and lead to 
more effective therapeutic options. The animal models described in this chapter are relevant 
for at least some key aspects of fibromyalgia patients. Combination of multiple animal 
models, each mimicking at least one key feature seen in fibromyalgia patients, may 
complement the comprehensive understanding of fibromyalgia pathophysiology. These and 
future animal models will be instrumental for developing more effective treatments for 
fibromyalgia. 
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Given the potential problems that can obscure any scientific enterprise, inconsistent results across studies are
bound to occur. How are we to decide what is true? Let's turn to philosophy for a reasonable answer. The
mathematician-philosopher Bertrand Russell approached a similar problem in his monograph The Problems of
Philosophy (Russell B, 1912). He addressed the following question: How do we know that anything is "real"? Is
the only reality subjective and simply in our minds, as Bishop Berkley challenged, or can we mostly believe the
objective reality? His pragmatic answer: All possibilities may be true, but when the preponderance of evidence
indicates that objective reality and knowledge are the most probable case, go with it. If the preponderance of
all evidence about the clinical description of fibromyalgia and it's pathogenic mechanisms and treatment
strategies indicate a highly probable interrelated hypothesis, go with it. The direction of the literature on the
whole trumps the less likely tangents. At the same time, remember Bertrand Russell and his pragmatic
answer, and keep an open mind.
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